Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2021 / 06:50PM GMT
Release Date Price: $81.85 (-0.70%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

All right. Great. So welcome, everyone, to Credit Suisse's 30th Annual Healthcare Conference. I'm Tiago Fauth. I'm a biotech analyst here at Credit Suisse. We're joined today by BioMarin. I have JJ on the line, Jeff and Brian. So I appreciate you guys participating.

Feel free to e-mail me any questions that you might have, and I'll try to work those into the fireside chat. The e-mail is [email protected]. And as usual, we can probably get started with some broad remarks, a recap of the year, key focus areas, and we'll start to go into a little bit more detail after that. But J.J., I don't know if you want to take it away.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Okay. Thank you. Thank you, Tiago. We appreciate the opportunity to join you today. So with just a few weeks left in 2021, we look forward to 2022 with great excitement as we consider the growth opportunity ahead, with potential U.S

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot